Pancreatic Cancer Research

ResearcherAnhui Medical UniversityActive in the last 2 years

Panling Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1592-5527; OpenAlex author ID A5009616195. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 8

  1. Migrasome-related LncRNA features predict immune microenvironment and prognosis in pancreatic cancer. Co-author DOI 10.1038/s41598-025-24226-x↗
  2. "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways. First author DOI 10.1177/2515690x241291381↗
  3. Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis. Co-author DOI 10.2174/0115680096274284231116104554↗
  4. Immune landscape and prognostic index for pancreatic cancer based on TCGA database and in vivo validation. Co-author DOI 10.1186/s12885-023-10597-9↗
  5. Brucea Javanica Oil Emulsion Injection inhibits proliferation of pancreatic cancer via regulating apoptosis-related genes. Co-author PMID 38058798↗
  6. Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation. Co-author DOI 10.1016/j.jep.2021.114691↗
  7. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer. First author DOI 10.1016/j.jep.2022.115516↗
  8. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. First author DOI 10.1186/s12863-021-01019-5↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chien‐shan Cheng · 4 shared papers, 2022–2024 · strength 0.85
  2. Shu Dong Ma · 4 shared papers, 2022–2024 · strength 0.82
  3. Ping Li · 3 shared papers, 2022–2025 · strength 0.73
  4. Juying Jiao · 3 shared papers, 2022–2024 · strength 0.61
  5. You Wu · 2 shared papers, 2023–2024 · strength 0.53
  6. Peiwen Yang · 2 shared papers, 2022–2024 · strength 0.42
  7. Lianyu Chen · 2 shared papers, 2022–2024 · strength 0.42
  8. Zhen Chen · 2 shared papers, 2022 · strength 0.35
  9. Hao Chen · 2 shared papers, 2022 · strength 0.35
  10. Ping Li · 1 shared paper, 2024 · strength 0.31
  11. Wenhao Li · 1 shared paper, 2025 · strength 0.30
  12. Ping Li · 1 shared paper, 2023 · strength 0.22
  13. Huifeng Gao · 1 shared paper, 2022 · strength 0.16
  14. Yujie Li · 1 shared paper, 2022 · strength 0.16
  15. Xiaoyan Zhu · 1 shared paper, 2022 · strength 0.16
  16. Ke Zhang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.